Larimar Therapeutics, Inc.LRMRNASDAQ
Loading
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q4 2025 | 31.95% |
| Q3 2025 | 92.28% |
| Q2 2025 | -11.99% |
| Q1 2025 | -0.70% |
| Q4 2024 | 92.10% |
| Q3 2024 | -29.28% |
| Q2 2024 | 53.06% |
| Q1 2024 | 21.69% |
| Q4 2023 | 60.47% |
| Q3 2023 | 12.09% |
| Q2 2023 | 28.78% |
| Q1 2023 | -36.80% |
| Q4 2022 | 29.31% |
| Q3 2022 | -1.10% |
| Q2 2022 | -2.79% |
| Q1 2022 | -7.72% |
| Q4 2021 | -55.15% |
| Q3 2021 | 54.12% |
| Q2 2021 | 1.43% |
| Q1 2021 | -15.13% |
| Q4 2020 | 52.83% |
| Q3 2020 | -22.32% |
| Q2 2020 | 77.89% |
| Q1 2020 | -7.38% |
| Q4 2019 | -32.71% |
| Q3 2019 | 156.84% |
| Q2 2019 | 73988.11% |
| Q1 2019 | -99.96% |
| Q4 2018 | -3.15% |
| Q3 2018 | -3.10% |
| Q2 2018 | -1.80% |
| Q1 2018 | 13.95% |
| Q4 2017 | 12.22% |
| Q3 2017 | -7.65% |
| Q2 2017 | 8.79% |
| Q1 2017 | 33.02% |
| Q4 2016 | -27.26% |
| Q3 2016 | -1.59% |
| Q2 2016 | -18.68% |
| Q1 2016 | -29.42% |